Home Deuterated Building Blocks 56862-28-3
56862-28-3,MFCD00272656
Catalog No.:AA00EEIF

56862-28-3 | (-)-N-DeMethyl Deprenyl

Pack Size
Purity
Availability
Price(USD)
Quantity
  
1mg
3 weeks  
$372.00   $260.00
- +
2.5mg
3 weeks  
$550.00   $385.00
- +
5mg
3 weeks  
$872.00   $610.00
- +
  • Technical Information
  • Properties
  • Literature
  • Request for Quotation
  • Download SDS
  • Technical Information
  • Properties
  • Literature
Technical Information
Catalog Number:
AA00EEIF
Chemical Name:
(-)-N-DeMethyl Deprenyl
CAS Number:
56862-28-3
Molecular Formula:
C26H40Cl2N2O6S
Molecular Weight:
579.5766
MDL Number:
MFCD00272656
SMILES:
CCCC1CN(C(C1)C(=O)NC(C1O[C@@H](SC)C(C2[C@H]1OC(O2)c1ccc(cc1)OC)O)C(Cl)C)C.Cl
Properties
Computed Properties
 
Complexity:
171  
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
1  
Heavy Atom Count:
13  
Hydrogen Bond Acceptor Count:
1  
Hydrogen Bond Donor Count:
1  
Rotatable Bond Count:
4  
XLogP3:
2.3  

Literature

Title: Cytoprotective effect of (-)-deprenyl, (-)desmethyl-deprenyl and (-)deprenyl-N-oxide on glutathione depleted A-2058 melanoma cells.

Journal: Journal of neural transmission (Vienna, Austria : 1996) 20100601

Title: A phase 1 trial of pharmacologic interactions between transdermal selegiline and a 4-hour cocaine infusion.

Journal: BMC clinical pharmacology 20090101

Title: P450 phenotyping of the metabolism of selegiline to desmethylselegiline and methamphetamine.

Journal: Drug metabolism and pharmacokinetics 20070401

Title: Pharmacokinetic studies of (-)-deprenyl and some of its metabolites in mouse.

Journal: Journal of neural transmission. Supplementum 20070101

Title: Simultaneous determination of selegiline and desmethylselegiline in human body fluids by headspace solid-phase microextraction and gas chromatography-mass spectrometry.

Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20061205

Title: High-performance liquid chromatographic-mass spectrometric determination of methamphetamine and amphetamine enantiomers, desmethylselegiline and selegiline, in hair samples of long-term methamphetamine abusers or selegiline users.

Journal: Journal of analytical toxicology 20060501

Title: Quantitative analysis of desmethylselegiline, methamphetamine, and amphetamine in hair and plasma from Parkinson patients on long-term selegiline medication.

Journal: Journal of analytical toxicology 20030401

Title: Protective effects of selegiline and desmethylselegiline against N-methyl-D-aspartate-induced rat retinal damage.

Journal: European journal of pharmacology 20030101

Title: Neuroprotection for Parkinson's disease: prospects and promises.

Journal: Annals of neurology 20030101

Title: Quantitative analysis of selegiline and three metabolites (N-desmethylselegiline, methamphetamine, and amphetamine) in human plasma by high-performance liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry.

Journal: Journal of analytical toxicology 20021001

Title: Urinary excretion of selegiline N-oxide, a new indicator for selegiline administration in man.

Journal: Xenobiotica; the fate of foreign compounds in biological systems 20020901

Title: Effect of concomitant hormone replacement therapy containing estradiol and levonorgestrel on the pharmacokinetics of selegiline.

Journal: European journal of clinical pharmacology 20020701

Title: Modulation of neuroendocrine--immune signaling by L-deprenyl and L-desmethyldeprenyl in aging and mammary cancer.

Journal: Mechanisms of ageing and development 20020430

Title: Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.

Journal: The Journal of biological chemistry 20020419

Title: CYP2C19 polymorphism is not important for the in vivo metabolism of selegiline.

Journal: European journal of clinical pharmacology 20010501

Title: Effects of an inhibitor of poly(ADP-ribose) polymerase, desmethylselegiline, trientine, and lipoic acid in transgenic ALS mice.

Journal: Experimental neurology 20010401

Title: Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole.

Journal: European journal of clinical pharmacology 20010401

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Tags:56862-28-3 Molecular Formula|56862-28-3 MDL|56862-28-3 SMILES|56862-28-3 (-)-N-DeMethyl Deprenyl